Company Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products.
The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011.
Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 487 |
| CEO | Barry Greene |
Contact Details
Address: 215 First Street Cambridge, Massachusetts 02142 | |
| Phone | 617 299 8380 |
| Website | sagerx.com |
Stock Details
| Ticker Symbol | SAGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001597553 |
| CUSIP Number | 78667J108 |
| ISIN Number | US78667J1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Barry E. Greene | President, Chief Executive Officer and Director |
| Kimi E. Iguchi CPA | Chief Financial Officer and Treasurer |
| Anne Marie Cook Esq. | Senior Vice President, General Counsel and Secretary |
| Christopher Benecchi | Chief Business Officer |
| Dr. Laura Gault M.D., Ph.D. | Chief Medical Officer |
| Matt Lasmanis | Chief Technology and Innovation Officer |
| Mike Quirk Ph.D. | Chief Scientific Officer |
| Ashley Kaplowitz | Director of Investor Relations |
| Erin E. Lanciani | Chief People and Experience Officer |
| Dr. Amy Schacterle Ph.D. | Senior Vice President of Research & Development Strategy and Business Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2024 | 8-K | Current Report |
| Sep 17, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 24, 2024 | 8-K | Current Report |
| Jun 25, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 11, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 8-K | Current Report |
| Jun 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |